IC
INBX icon

Ikarian Capital’s Inhibrx INBX Stock Holding History

Ikarian Capital’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,122
Closed -$601K – 183
2025
Q2 		$601K Hold
42,122
– – 0.12% 89
2025
Q1 		$589K Hold
42,122
– – 0.07% 111
2024
Q4 		$649K Sell
42,122
-1
-0% -$15 0.09% 123
2024
Q3 		$660K Sell
42,123
-187,877
-82% -$2.64M 0.09% 113
2024
Q2 		$3.26M Buy
+230,000
New +$3.59M 0.57% 41

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's INBX Position: Q3 2025 in Review

Ikarian Capital sold out of Inhibrx (INBX) in Q3 2025, closing a stake of 42,122 shares — an estimated $601K sold.

Ikarian Capital first reported a position in INBX in Q2 2024 and held it in 5 quarters. The position peaked at $3.26M in Q2 2024. 102 funds tracked by Wall St. Rank hold INBX as of Q3 2025.

  • Ikarian Capital reported no remaining Inhibrx position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 42,122 Inhibrx shares in Q3 2025, an estimated $601K.
  • Ikarian Capital first reported a position in Inhibrx in Q2 2024 and held it in 5 quarters.
  • Ikarian Capital's Inhibrx position peaked at $3.26M in Q2 2024.
  • 102 funds tracked by Wall St. Rank held Inhibrx as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.